ProCE Banner Activity

KEYNOTE-522 Study of Neoadjuvant Pembrolizumab vs Placebo in Combination With Chemotherapy for Early-Stage TNBC: Subgroup Analysis of pCR

Slideset Download
Conference Coverage
Neoadjuvant pembrolizumab plus chemotherapy associated with pCR benefit vs chemotherapy alone in patients with early-stage TNBC across multiple subgroups.

Released: December 19, 2019

Expiration: December 17, 2020

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Daiichi Sankyo, Inc.

Genentech TEXT Only

Merck Sharp & Dohme Corp.

Puma Biotechnology, Inc.

Seagen